Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background Aberrant promoter hypermethylation is an epigenetic change that silences the expression of crucial genes, resulting in inactivation of the apoptotic pathway in various cancers. This hypermethylation can be restored by the demethylating agent 5-aza-2'-deoxycytidine (DAC). DAC might increase the tumor sensitivity to chemotherapy through demethylation and restoration of gene expression. We investigated the effect of combined therapy with DAC and irinotecan (CPT-11) on the human colon cancer cell line HCT-15.Methods Human colon cancer cell line HCT-15 was treated with DAC and/or CPT-11 both in vitro and in vivo. The changes in mRNA expression of several apoptosis-related genes were investigated by reverse transcriptase-polymerase chain reaction (PCR). Promoter methylation was detected by methylation-specific PCR and combined bisulfite restriction analysis. Suppression of tumor growth was observed during the treatment with DAC and/or CPT-11 and apoptosis in the tumors was investigated by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) assay.Results Promoter methylation of p14ARF, p16 INK4a, BNIP3, and XAF1 was confirmed, and DAC restored mRNA expression of these genes. Demethylation and restoration of gene expression was observed with low-dose DAC, and demethylation status was sustained for several weeks. Combined therapy with DAC and CPT-11 produced marked suppression in tumor growth compared with DAC or CPT-11 alone, both in vitro and in vivo.Conclusions Pretreatment with low-dose DAC may have the potential to be used as a "biosensitizer" of DNA-damaging agents such as CPT-11 when the apoptotic pathway is inactivated as a result of aberrant promoter methylation in the cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, multiple DNMT inhibitors exhibited additive or synergistic effects when combined with 5-FU, oxaliplatin or irinotecan in CRC cell lines [159,160,161].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [159]
Citations
Cites
1 retracted
Normand, G., Hemmati, P., Verdoodt, B., von Haefen, C., Wendt, J., Güner, D., May, E., Dörken, B., & Daniel, P. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412330200 · Cited by 56
RetractedMethylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 4×
“Colorectal cancer (CRC) is one of the most common malignancies worldwide.1 Chemotherapy is an important treatment strategy for metastatic CRC.”
BackgroundInfluentialFrommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., & Paul, C. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1827 · Cited by 3,238
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Cellular differentiation, cytidine analogs and DNA methylation
Jones, P. A., & Taylor, S. M. (1980) · Cell · doi:10.1016/0092-8674(80)90237-8 · Cited by 1,831 · cited 1×
“DAC traps the DNA methyltransferase enzyme in a covalent complex with the DNA, resulting in a loss of DNA methylation with each cycle of cell division.(14,15) Many studies demonstrated that treatment with DAC restored the expression and the functions of a number of crucial tumor suppressor genes such as p14 and suppre…”
BackgroundCOBRA: a sensitive and quantitative DNA methylation assay
Xiong, Z., & Laird, P. W. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.12.2532 · Cited by 1,195
Weitz, J., Koch, M., Debus, J., Höhler, T., Galle, P. R., & Büchler, M. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17706-x · Cited by 1,098
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Vande Velde, C., Cizeau, J., Dubik, D., Alimonti, J., Brown, T., Israels, S., Hakem, R., & Greenberg, A. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5454-5468.2000 · Cited by 619
Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
A systematic profile of DNA methylation in human cancer cell lines.
Paz, M. F., Fraga, M. F., Avila, S., Guo, M., Pollán, M., Herman, J. G., & Esteller, M. (2003) · PubMed · Cited by 420
The E1B 19K/Bcl-2–binding Protein Nip3 is a Dimeric Mitochondrial Protein that Activates Apoptosis
Chen, G., Ray, R., Dubik, D., Shi, L., Cizeau, J., Bleackley, R. C., Saxena, S., Gietz, R. D., & Greenberg, A. H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.1975 · Cited by 332
DNA methyltransferase inhibitors—state of the art
Goffin, J., & Eisenhauer, E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf314 · Cited by 283
Arnold, C. N., Goel, A., & Boland, C. R. (2003) · International Journal of Cancer · doi:10.1002/ijc.11176 · Cited by 280
Silencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in Pancreatic Cancer
Okami, J., Simeone, D. M., & Logsdon, C. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0089 · Cited by 238
Expression and Genetic Analysis of XIAP-Associated Factor 1 (XAF1) in Cancer Cell Lines
Fong, W. G., Liston, P., Rajcan-Separovic, E., St. Jean, M., Craig, C., & Korneluk, R. G. (2000) · Genomics · doi:10.1006/geno.2000.6364 · Cited by 213
Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A., Chambaz, J., Lacorte, J., Staedel, C., & Lesuffleur, T. (2002) · International Journal of Cancer · doi:10.1002/ijc.10146 · Cited by 213
Mechanisms of resistance to topoisomerase I-targeting drugs
Rasheed, Z. A., & Rubin, E. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206935 · Cited by 180
Tan, K. B., Mattern, M. R., Eng, W.-K., McCabe, F. L., & Johnson, R. K. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.22.1732 · Cited by 171
Ichikawa, W., Uetake, H., Shirota, Y., Yamada, H., Nishi, N., Nihei, Z., Sugihara, K., & Hirayama, R. (2003) · PubMed · Cited by 167
Self-citationHagiwara, K., McMenamin, M. G., Miura, K., & Harris, C. C. (1999) · PubMed · Cited by 144
Samlowski, W. E., Leachman, S. A., Wade, M., Cassidy, P., Porter-Gill, P., Busby, L., Wheeler, R., Boucher, K., Fitzpatrick, F., Jones, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.118 · Cited by 139
Teodoridis, J. M., Strathdee, G. R., & Brown, R. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.06.005 · Cited by 136
Byun, D.-S., Cho, K., Ryu, B., Lee, M. G., Kang, M. J., Kim, H. R., & Chi, S. (2003) · PubMed · Cited by 134
The Orphan Nuclear Receptor NGFIB Regulates Transcription of 3β-Hydroxysteroid Dehydrogenase
Bassett, M. H., Suzuki, T., Sasano, H., de Vries, C. J. M., Jimenez, P. T., Carr, B. R., & Rainey, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405431200 · Cited by 126
Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis
Hemmati, P., Gillissen, B. F., von Haefen, C., Wendt, J., Stärck, L., Güner, D., Dörken, B., & Daniel, P. T. (2002) · Oncogene · doi:10.1038/sj.onc.1205458 · Cited by 124
Arf induces p53-dependent and -independent antiproliferative genes.
Kuo, M.-L., Duncavage, E. J., Mathew, R., den Besten, W., Pei, D., Naeve, D., Yamamoto, T. S., Cheng, C., Sherr, C. J., & Roussel, M. F. (2003) · PubMed · Cited by 121
Phase I trial of continuous infusion 5-aza-2′-deoxycytidine
Aparicio, A. M., Eads, C. A., Leong, L., Laird, P. W., Newman, E. M., Synold, T. W., Baker, S. D., Zhao, M., & Weber, J. S. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0563-y · Cited by 119
Molecular, cellular and animal pharmacology of 5-AZA-2′-deoxycytidine
Momparler, R. L. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90053-1 · Cited by 95
Lavelle, D., DeSimone, J., Hankewych, M., Kousnetzova, T., & Chen, Y.-H. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00068-7 · Cited by 94
Alterations and hypermethylation of thep14ARF gene in gastric cancer
Iida, S., Akiyama, Y., Nakajima, T., Ichikawa, W., Nihei, Z., Sugihara, K., & Yuasa, Y. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000901)87:5<654::aid-ijc6>3.0.co;2-p · Cited by 93
Self-citationPeták, I., Danam, R. P., Tillman, D. M., Vernes, R., Howell, S. R., Berczi, L., Kopper, L., Brent, T. P., & Houghton, J. A. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401132 · Cited by 91
Pohlmann, P. R., Leone, L. P. D., Cancella, A., Caldas, A. P. F., Lago, L. D., Campos, O., Monego, E., Rivoire, W. A., & Schwartsmann, G. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200210000-00015 · Cited by 87
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.
Aparicio, A. M., & Weber, J. S. (2002) · PubMed · Cited by 84
Bras-Gonçalves, R., Rosty, C., Laurent‐Puig, P., Soulié, P., Dutrillaux, B., & Poupon, M. F. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1019 · Cited by 75
Uetake, H., Ichikawa, W., Takechi, T., Fukushima, M., Nihei, Z., & Sugihara, K. (1999) · PubMed · Cited by 74
Self-citationWidschwendter, M., & Jones, P. A. (2002) · PubMed · Cited by 64
Mutational analysis of p73 and p53 in human cancer cell lines
Yoshikawa, H., Nagashima, M., Ma, K., McMenamin, M. G., Hagiwara, K., & Harris, C. C. (1999) · Oncogene · doi:10.1038/sj.onc.1202677 · Cited by 64
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
ANZAI, H., Frost, P., & Abbruzzese, J. L. (1992) · PubMed · Cited by 40
SN-38 Induces Cell Cycle Arrest and Apoptosis in Human Testicular Cancer
Ueno, M., Nonaka, S., Yamazaki, R., Deguchi, N., & Murai, M. (2002) · European Urology · doi:10.1016/s0302-2838(02)00321-4 · Cited by 40
Low expression of XIAP‐associated factor 1 in human colorectal cancers
Tian Le, M. A., Pei Hua, N. I., Zhong, J., Ji Hong, T. A. N., Min Min, Q. I. A. O., & Jiang, S. H. (2005) · Chinese Journal of Digestive Diseases · doi:10.1111/j.1443-9573.2005.00180.x · Cited by 29
The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer
Widschwendter, M., & Jones, P. (2002) · UCL Discovery (University College London) · Cited by 21
[Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
Nishimura, G., Satou, T., Yoshimitsu, Y., Kurosaka, Y., Fujimura, T., Sugiyama, K., Kanno, M., Yonemura, Y., Miwa, K., & Miyazaki, I. (1995) · PubMed · Cited by 13
Aoyagi, Y., Kobunai, T., Utsugi, T., Wierzba, K., & Yamada, Y. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00979.x · Cited by 8
Cited by
DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines
Roll, J. D., Rivenbark, A. G., Jones, W. D., & Coleman, W. B. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-15 · Cited by 224
The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death
Burton, T. R., & Gibson, S. B. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.185 · Cited by 216
Khamas, A., Ishikawa, T., Shimokawa, K., Mogushi, K., Iida, S., Ishiguro, M., Mizushima, H., Tanaka, H., Uetake, H., & Sugihara, K. (2012) · PubMed · Cited by 141
Self-citationEpigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 118
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94
Metadata
- Authors
- Ishiguro, M., Iida, S., Uetake, H., Morita, S., Makino, H., Kato, K., Takagi, Y., Enomoto, M., & Sugihara, K.
- Affiliations
- Tokyo Medical and Dental University (JP)
- Corresponding author
- Ishiguro, Megumi
- Venue
- Annals of Surgical Oncology
- Published
- 2006-12-31
- Volume
- 14
- Issue
- 5
- Pages
- 1752-1762
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- OpenAlex
- W2004617245
- Cited by
- 43
- References
- 50
- Citations by year
- 2025: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 7
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Annals of Surgical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- decitabine, irinotecan, colon cancer, promoter hypermethylation, DNA demethylation, epigenetic silencing, apoptosis, p14ARF, p16INK4a, BNIP3, XAF1, combination chemotherapy, tumor growth inhibition
- MeSH terms
- Irinotecan, Decitabine, Animals, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Camptothecin, Colonic Neoplasms, Drug Therapy, Combination, Humans, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Nude, Neoplasm Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, RNA, Messenger, Gene Expression Regulation, Neoplastic, Survival Rate, Apoptosis, DNA Methylation, Cyclin-Dependent Kinase Inhibitor p16, Reverse Transcriptase Polymerase Chain Reaction, In Situ Nick-End Labeling, Tumor Suppressor Protein p14ARF, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Cell Proliferation, Apoptosis Regulatory Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.